ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Assessment Questionnaire (HAQ)"

  • Abstract Number: 0758 • ACR Convergence 2020

    Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients

    Dana Wiens1, Irene Smolik1, Xiaobo Meng1, Vidyanand Anaparti1, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…
  • Abstract Number: 1335 • ACR Convergence 2020

    Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register

    Dominic Seet1, Li Wearn Koh2, Preeti Dhanasekaran3, Man Hua Aw4, Rosa Lim Mui San2, Siaw Ing Yeo4 and Manjari Lahiri1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Singapore General Hospital, Singapore, Singapore

    Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
  • Abstract Number: 1363 • ACR Convergence 2020

    Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial

    Vibeke Strand1, Gurjit Kaeley2, Martin Bergman3, Dafna Gladman4, Laura Coates5, Peter Hur6, Nina Kim7, Bhumik Parikh6, Patricia Pertel8 and Philip Mease9, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2University of Florida College of Medicine - Jacksonville, Jacksonville, FL, 3Drexel University College of Medicine, Philadelphia, PA, 4Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 5University of Oxford, Oxford, United Kingdom, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, 8Novartis AG, Basel, Switzerland, 9Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…
  • Abstract Number: 1577 • ACR Convergence 2020

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

    Jeffrey Sarazin1, Ann Impens2, Nada Abdulaziz1, Stacey Anderson3, Leslie Fecher1, Christopher Lao1 and Elena Schiopu1, 1Michigan Medicine, Ann Arbor, MI, 2Midwestern University, Ann Arbor, IL, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
  • Abstract Number: 1736 • ACR Convergence 2020

    Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis

    Safoora Fatima1, Orit Schieir2, Marie-France Valois3, Susan Bartlett3, Louis Bessette4, Gilles Boire5, Glen Hazlewood6, Carol Hitchon7, Edward C Keystone8, Diane Tin9, Carter Thorne9, Vivian Bykerk10, Janet Pope11 and Canadian Early Arthritis Cohort (CATCH) Investigators12, 1University of Western Ontario, London, ON, Canada, 2Canadian Early Arthritis Cohort Study, Montreal, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec, Canada, 5Universite de Sherbrooke, Sherbrooke, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Hospital for Special Surgery, New York, NY, 11Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 12Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Patients with RA are at greater risk of mortality than the general population. Higher HAQ disability has been associated with hospitalizations and mortality in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology